Sandhya Girish

Vice President, Head Clinical Pharmacology, Pharmacometrics and Bioanalytical Sciences

Gilead Sciences

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sandhya Girish is the Vice President and Head of Clinical Pharmacology, Pharmacometrics, and Bioanalytical Sciences at Gilead Sciences in the United States. Her research areas include population pharmacokinetics, exposure–response analyses, and the modeling of viral and immune dynamics in HIV. She has contributed significantly to studies on therapies for metastatic breast cancer and the impact of COVID-19 on clinical trial design.

Articles (7)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Whitney Kirschbrown

University of South Florida

UNITED STATES

View details

Iñaki F. Trocóniz

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sandhya Girish

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Modeling the Interplay Between Viral and Immune Dynamics in HIV: A Review and Mrgsolve Implementation and Exploration

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial

Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer

Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation

Collaborators (2)

Whitney Kirschbrown

Iñaki F. Trocóniz

Make your next move.